- Business Insider•4 days ago
Pharmacists around the country are agitated. For years they've been watching their customers...
- Forbes•5 days ago
Now that AstraZeneca’s transition to the cloud is largely in place, it is seeing broad business benefits across the organization. Cloud-based solutions enabled AstraZeneca to implement work faster than legacy tools would have allowed. The company is also taking advantage of the efficiency of the cloud model, including a reduction in capital expenditure, the ability to scale up and down, and the fact that it needs fewer people to support apps like Workday or ServiceNow as compared to SAP.
- Zacks•6 days ago
AstraZeneca plc (AZN) announced that the FDA has accepted for review its complete re-submission of the new drug application (NDA) for ZS-9 (sodium zirconium cyclosilicate).
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||4,800.00 x 6100|
|Ask||5,100.00 x 13000|
|Day's Range||4,835.50 - 5,011.79|
|52wk Range||3,680.00 - 5,505.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||27.72|
|Avg Vol (3m)||2,581,370|
|Dividend & Yield||N/A (N/A)|